Multiple Myeloma: all 3,712 studies
Page 6 of 38. Open to participants first (752), then studies with results posted, then the rest; newest registration first within each.
- Cyclin D1 as a Prognostic Factor in Multiple Myeloma and Its Association With the Immunological Prognostic Factor PDL1 and Clinical and Biochemical Lab TestsNot yet recruitingNCT05995808Not applicable
- GammaGA: Prevalence of Acid Sphingomyelinase Deficiency Disease (ASMD) and Gaucher Disease in Patients With Monoclonal Gammopathies and/or Multiple MyelomaRecruitingNCT05992532
- Trial of an Investigational Drug After Rejecting the Relapse of an Allogeneic TransplantNot yet recruitingNCT05982275Phase 1/2
- Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory MyelomaRecruitingNCT05976555Phase 1
- Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom MonitoringRecruitingNCT05974150
- Outpatient Administration of Teclistamab or Talquetamab for Multiple MyelomaRecruitingNCT05972135Phase 2
- Helical Tomotherapy in Multiple MyelomaRecruitingNCT05970198Not applicable
- At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced CancerRecruitingNCT05969860Phase 2
- Myeloma Novel Drug Discovery Ver 1.2RecruitingNCT05968417
- The China M-protein Screening Project in First-degree Relatives of Myeloma Patient - The CHAPERONE StudyRecruitingNCT05965115
- Telemonitoring Among Patients With Multiple MyelomaRecruitingNCT05964270Not applicable
- PRO and Wearable Data Insights From Individuals With R/R Multiple MyelomaRecruitingNCT05956457Not applicable
- PASCA-MM Study. Impact of the PASCA (PArcours de Santé au Cours du CAncer) Program on Complications Associated With Multiple Myeloma and/or Its Treatments in the Context of a First Hematopoietic Stem Cell Autograft, in Adults Aged 18 to 70.RecruitingNCT05947136Not applicable
- Analysis of the Resistance and Sensitivity Mechanisms to Teclistamab by Focusing on Single Immune Cell ExaminationRecruitingNCT05945524Not applicable
- Bioequivalence Studies of Dasatinib 100 MgNot yet recruitingNCT05944783Phase 4
- Limited-duration TeclistamabRecruitingNCT05932680Phase 2
- A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)RecruitingNCT05927571Phase 1
- Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple MyelomaRecruitingNCT05922501Phase 2
- A Study of QLS32015 in Patients With Recurrent or Refractory Multiple MyelomaRecruitingNCT05920876Phase 1
- YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple MyelomaRecruitingNCT05913804Phase 1
- Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMMNot yet recruitingNCT05909826Phase 2
- CAR T-cell Therapy in Patients With Renal DysfunctionRecruitingNCT05909059Phase 2
- A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic MalignanciesRecruitingNCT05908409Phase 1/2
- Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple MyelomaRecruitingNCT05896228Phase 2
- Assess the Safety and Efficacy of CT0594CP Cells in Relapsed/Refractory Multiple Myeloma or Plasma Cell LeukemiaRecruitingNCT05893693Not applicable
- Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple MyelomaRecruitingNCT05892393Phase 1
- Transcriptomics and Epigenetics Analysis in Drug-Resistance of Multiple MyelomaRecruitingNCT05888636
- Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological MalignanciesRecruitingNCT05887167Phase 1
- GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic MalignanciesRecruitingNCT05880043Phase 1/2
- Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary ImmunodeficiencyRecruitingNCT05879757
- Discontinuation StudyRecruitingNCT05866757Not applicable
- Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)RecruitingNCT05862012Phase 1
- Examination of Trends in Multiple Myeloma Trial Patient ExperiencesNot yet recruitingNCT05860179
- Inhibition of Che-1/AATF as a New Tool in Multiple Myeloma TreatmentRecruitingNCT05858203
- Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple MyelomaRecruitingNCT05857982Phase 1/2
- Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma PatientsRecruitingNCT05855122Phase 4
- Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple MyelomaRecruitingNCT05853965Phase 1/2
- AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)RecruitingNCT05850234Phase 1/2
- Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple MyelomaRecruitingNCT05847569Phase 2
- VitD3 Supplementation in Patients With Multiple MyelomaRecruitingNCT05846880Early Phase 1
- The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple MyelomaRecruitingNCT05841550Phase 1/2
- Study of FasT CAR-T GC012F Injection NDMM PatientsRecruitingNCT05840107Early Phase 1
- A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell MalignanciesRecruitingNCT05836896Phase 1
- A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received TreatmentRecruitingNCT05828511Phase 1/2
- CT0594CP CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell LeukemiaRecruitingNCT05822037Not applicable
- Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple MyelomaRecruitingNCT05789303Phase 2
- Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma PatientsRecruitingNCT05776979Phase 2
- ASH Research Collaborative Data HubEnrolling by invitationNCT05775224
- DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.RecruitingNCT05768178Phase 2/3
- A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell LeukemiaRecruitingNCT05759793Phase 1
- Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MMRecruitingNCT05749133Phase 1/2
- Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MMRecruitingNCT05739188Phase 1/2
- The Ambient Light Multiple Myeloma StudyRecruitingNCT05737732Not applicable
- Early Detection and Screening of Hematological Malignancies - SANGUINERecruitingNCT05735704
- A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple MyelomaRecruitingNCT05730036Phase 3
- CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple MyelomaRecruitingNCT05722418Phase 1
- Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple MyelomaRecruitingNCT05722405Phase 4
- Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple MyelomaRecruitingNCT05719701Phase 1/2
- A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination TreatmentsRecruitingNCT05714839Phase 1/2
- Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell TransplantationRecruitingNCT05706766Not applicable
- A Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT05698303Phase 1
- GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5RecruitingNCT05695508Phase 2
- Screening and Therapeutic Monitoring of Multiple Myeloma by MALDI-TOF MS AnalysisRecruitingNCT05686447
- International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From IsatuximabEnrolling by invitationNCT05669989Phase 2
- Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma PatientsRecruitingNCT05665140Phase 2/3
- A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) AmyloidosisRecruitingNCT05652335Phase 1
- A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple MyelomaRecruitingNCT05651932Phase 1
- A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT05650632Phase 1
- A Clinical Trial of TQB2934 for Injection in Multiple Myeloma SubjectsRecruitingNCT05646758Phase 1
- Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular TherapyRecruitingNCT05646576Not applicable
- LIVInG With chrONic Cancer TrEatments (LONGEVITI) StudyRecruitingNCT05645510
- Prehabilitation Feasibility Among Older Adults Undergoing TransplantationRecruitingNCT05642884Not applicable
- Clinical Trial Investigating the Chemotherapeutic Compound Treosulfan (Trecondi® Ideogen) in Myeloma PatientsRecruitingNCT05636787Phase 2
- ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)RecruitingNCT05632380Phase 1/2
- A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for TransplantRecruitingNCT05623020Phase 3
- The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological MalignanciesRecruitingNCT05618041Not applicable
- Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple MyelomaRecruitingNCT05597345Phase 2
- Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MMRecruitingNCT05594797Phase 2
- A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple MyelomaRecruitingNCT05583617Phase 1/2
- A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide RefractoryNot yet recruitingNCT05581875Phase 1/2
- ctDNA Methylation Sequencing for MyelomaRecruitingNCT05578625
- A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple MyelomaRecruitingNCT05573802Phase 1/2
- Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple MyelomaRecruitingNCT05565807Phase 1/2
- Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable TreatmentRecruitingNCT05561387Phase 3
- Efficacy and Safety of Daratumumab in Combination With Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple MyelomaNot yet recruitingNCT05561049
- Real-World Use of Selinexor, Daratumumab and Dexamethasone in Chinese Patients With Multiple Myeloma at First RelapseNot yet recruitingNCT05559788
- Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme RegistryRecruitingNCT05556928
- A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaRecruitingNCT05552222Phase 3
- LMY-920 for Treatment of Relapsed or Refractory MyelomaRecruitingNCT05546723Phase 1
- A Randomized, Comparative, Double-blind Trial of Pentaisomaltose and Dimethyl Sulphoxide for Cryoprotection of Hematopoietic Stem Cells in Subjects With Multiple Myeloma or Malignant Lymphoma With a Need for Autologous TransplantationNot yet recruitingNCT05545202Phase 4
- Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological MalignanciesRecruitingNCT05536154Not applicable
- Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple MyelomaRecruitingNCT05530421Phase 2
- Telo Genomics Technology to Detect & Profile Multiple Myeloma MRDRecruitingNCT05530096
- A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple MyelomaRecruitingNCT05521802Phase 1/2
- A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)RecruitingNCT05519085Phase 3
- Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma(rr/MM)RecruitingNCT05509530Phase 2
- Selinexor, Pomalidomide, and Dexamethasone For Multiple Myeloma With CNS InvolvementRecruitingNCT05478993Phase 2
- Id and Rd Maintenance Regimens After Induction of Remission in Multiple Myeloma.RecruitingNCT05477797Not applicable
- Immuno-PRISM (PRecision Intervention Smoldering Myeloma)RecruitingNCT05469893Phase 2
- Compassionate Communication and Advance Care Planning to Improve End of Life Care in Treatment of Hematological Disease (ACT)RecruitingNCT05444348Not applicable